Pelizaeus-Merzbacher Disease: A Case Report

  • Ghazaleh Jamalipour Soufi ORCID Mail Department of Radiology, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Siavash Iravani ORCID School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Keywords:
Pelizaeus-merzbacher disease, Central nervous system (CNS), Magnetic resonance imaging (MRI), Genetic disorder, Nervous system disease

Abstract

Pelizaeus-Merzbacher Disease (PMD), as a rare genetically x-linked leukodystrophy, is a disorder of proteolipid protein expression in myelin formation. This disorder is clinically presented by neurodevelopmental delay and abnormal pendular eye movements. The responsible gene for this disorder is the proteolipid protein gene (PLP1). Our case was a oneyear- old boy referred to the radiology department for evaluating the Central Nervous System (CNS) development by brain Magnetic Resonance Imaging (MRI). Clinically, he demonstrated neuro-developmental delay symptoms. The brain MRI results indicated a diffuse lack of normal white matter myelination. This case report should be considered about the possibility of PMD in the brain MRI of patients who present a diffuse arrest of normal white matter myelination.

References

[1] Bizzi A, Castelli G, Bugiani M, Barker PB, Herskovits EH, Danesi U, et al. Classification of childhood white matter disorders using proton MR spectroscopic imaging. AJNR. American Journal of Neuroradiology. 2008; 29(7):1270-5. [DOI:10.3174/ajnr.A1106] [PMID] [PMCID]
[2] Pizzini F, Fatemi AS, Barker PB, Nagae-Poetscher LM, Horsk√° A, Zimmerman AW, et al. Proton MR spectroscopic imaging in Pelizaeus- Merzbacher disease. American Journal of Neuroradiology (AJNR). 2003; 24(8):1683-9. [DOI:10.1177/197140090301600320] [PMID]
[3] van der Knaap MS, Valk J. Pelizaeus-Merzbacher disease and X-linked spastic paraplegia type 2. In: van der Knaap MS, Valk J. Magnetic Resonance of Myelination and Myelin Disorders. Berlin/Heidelberg: Springer; 2005. pp. 272-80. [DOI:10.1007/3-540-27660-2_34]
[4] Yool D, Edgar J, Montague P, Malcolm S. The proteolipid protein gene and myelin disorders in man and animal models. Journal of the Peripheral Nervous System. 2000; 5(4):243. [DOI:10.1111/ j.1529-8027.2000.22-28.x]
[5] Shy ME, Hobson G, Jain M, Boespflug-Tanguy O, Garbern J, Sperle K, et al. Schwann cell expression of PLP1 but not DM20 is necessary to prevent neuropathy. Annals of Neurology. 2003; 53(3):354-65. [DOI:10.1002/ana.10466] [PMID] [PMCID]
[6] Barkovich AJ, Raybaud C. Pediatric neuroimaging. 5th Edition. 2012. Lippincott Williams and Wilkins, Philadelphia.
[7] Woodward KJ. The molecular and cellular defects underlying Pelizaeus- Merzbacher disease. Expert Reviews in Molecular Medicine. 2008; 10:e14. [DOI:10.1017/S1462399408000677] [PMID]
[8] Seitelberger F. Neuropathology and genetics of Pelizaeus- Merzbacher disease. Brain Pathology. 1995; 5(3):267-73. [DOI:10.1111/j.1750-3639.1995.tb00603.x] [PMID]
[9] Karimzadeh P, Ahmadabadi F, Aryani O, Houshmand M, Khatami A. New mutation of Pelizaeus-Merzbacher-like disease: A report from Iran. Iranian Journal of Radiology. 2014; 11(2):e6913. [DOI:10.5812/ iranjradiol.6913] [PMID] [PMCID]
[10] Sumida K, Inoue K, Takanashi J, Sasaki M, Watanabe K, Suzuki M, et al. The magnetic resonance imaging spectrum of Pelizaeus-Merzbacher disease: A multicenter study of 19 patients. Brain & Development. 2016; 38(6):571-80. [DOI:10.1016/j.braindev.2015.12.007] [PMID]
Published
2020-08-30
How to Cite
1.
Jamalipour Soufi G, Iravani S. Pelizaeus-Merzbacher Disease: A Case Report. CRCP. 5(2):51-54.
Section
Case Report(s)